Compare XBIT & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | JRVR |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 288.2M |
| IPO Year | 2015 | 2014 |
| Metric | XBIT | JRVR |
|---|---|---|
| Price | $2.35 | $4.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 26.2K | ★ 393.3K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $3.76 |
| 52 Week High | $3.61 | $7.20 |
| Indicator | XBIT | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 42.93 |
| Support Level | $2.35 | $3.78 |
| Resistance Level | $2.41 | $4.42 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 13.60 | 74.00 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.